AXBIO

elsewhere's corpus does not cover AXBIO directly — no article in the bundle is actually about the company. The only material that names it is a set of funding-round relations from 5Y Capital's 2022 reporting: AXBIO (also referred to as 安序源) raised a nearly $100 million Series B in mid-2022, co-led by AstraZeneca CICC Medical Industry Fund and Yunfeng Capital, with CBC Group, SDIC Meridian, and 5Y Capital among the followers ; 5Y Capital had previously led its A+ round in October 2021 . Beyond these financing details, the bundle offers no profile of what AXBIO does, its technology, or its team.